ArticleVirology journal2025
Prevalence, dynamic change and spatial distribution of HIV-1 CRF119_0107 from 2019 to 2024 in Nanjing, China: a genomic and spatial epidemiological analysis.
Article in Virology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundSince its initial detection among men who have sex with men (MSM) in Nanjing, CRF119_0107 has rapidly emerged as the third most prevalent HIV-1 subtype. To elucidate its transmission dynamic, spatial characteristics, and the prevalence of transmitted drug resistance (TDR), we conducted a joint genomic and spatial epidemiological analysis.
methodsHIV-infected individuals diagnosed from 2109 to 2024 who were identified as CRF119_0107 and didn't undergo antiretroviral therapy (ART) were included in the study. The HIV-1 pol gene sequence was obtained by viral RNA extraction and nested PCR. A molecular transmission network was constructed using HIV-TRACE, and spatial analysis was performed in ArcGIS. Multivariate logistic regression was employed to analyze factors associated with clustering. Transmission links of the network were visualized in intensity matrices and spatial transmission graph.
resultsThe 138 CRF119_0107 individuals predominantly consisted of unmarried, college-educated MSM. A notably high TDR prevalence of 15.9% was observed, with 15.2% (21/138) resistance to non-nucleoside reverse transcriptase inhibitor (NNRTI). At the genetic distance threshold of 0.005 substitutions/site, 78 sequences formed 11 transmission clusters, with a clustering rate of 56.6%. The transmission network analysis identified a drug-resistant cluster containing 19 drug-resistant individuals, all harboring K103N/KN mutation. Four large MSM-dominated clusters were identified, including two high-growth clusters expanding at over 2 nodes per year between 2022 and 2024. Multivariate logistic regression analysis revealed that individuals with high initial CD4 counts and TDR individuals had significantly higher clustering rate compared to those with CD4 counts < 200 cells/µL and without TDR. Spatial analysis revealed no significant autocorrelation in clustering rate at the district-level (Moran's I=-0.121, P = 0.774). Intensity matrices revealed extensive inter-district transmission across all 12 districts, with this transmission accounting for 83.8% of total transmissions. The spatial transmission graph showed that the strength of the connections between districts varied, and strong inter-district transmission linkages were also observed between geographically non-adjacent districts.
conclusionsReal-time surveillance and rapid response mechanisms should prioritize high-growth or drug-resistant transmission clusters. Cross-district coordination and joint interventions should be strengthened in districts with intensive transmission linkages. Our interdisciplinary approach offers an evidence-based framework for curbing dissemination of CRF119_0107.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.